AR111000A1 - BISPECIFIC UNION MOLECULES THAT ARE ABLE TO JOIN CD137 AND TUMOR ANTIGENS, AND USES OF THE SAME - Google Patents
BISPECIFIC UNION MOLECULES THAT ARE ABLE TO JOIN CD137 AND TUMOR ANTIGENS, AND USES OF THE SAMEInfo
- Publication number
- AR111000A1 AR111000A1 ARP180100436A ARP180100436A AR111000A1 AR 111000 A1 AR111000 A1 AR 111000A1 AR P180100436 A ARP180100436 A AR P180100436A AR P180100436 A ARP180100436 A AR P180100436A AR 111000 A1 AR111000 A1 AR 111000A1
- Authority
- AR
- Argentina
- Prior art keywords
- epitope
- binding
- molecules
- specific
- bispecific
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente se dirige a moléculas de unión que poseen uno o más sitios de unión a epítopo específicos para un epítopo de CD137 y uno o más sitios de unión a epítopo específicos para un epítopo de un antígeno tumoral (“TA”) (por ejemplo, una “Molécula de Unión a CD137 x TA”). En una modalidad, tales Moléculas de Unión a CD137 x TA serán moléculas biespecíficas, especialmente diacuerpos tetravalentes biespecíficos, que se componen de dos, tres, cuatro o más de cuatro cadenas polipeptídicas y que poseen dos sitios de unión a epítopo cada uno específico de un epítopo de CD137 y dos sitios de unión a epítopo cada uno especifico de un epítopo de un TA. Alternativamente, tales Moléculas de Unión a CD137 x TA serán moléculas biespecíficas, especialmente moléculas biespecíficas de unión trivalente compuestas de tres o más cadenas polipeptídicas y que poseen uno o dos sitios de unión a epítopo cada uno específico de un epítopo de CD137 y uno o dos sitios de unión a epítopo cada uno específico de un epítopo de un TA. Las Moléculas de Unión a CD137 x TA son capaces de unirse simultáneamente a CD137, y a un TA. Composiciones farmacéuticas que contienen cualquier Molécula de Unión a CD137 x TA. Métodos para el uso de tales moléculas en el tratamiento de cáncer y otras enfermedades y padecimientos. También proporciona moléculas de unión a CD137, y moléculas de unión a HER2/neu, así como derivados de las mismas y usos de las mismas.This is directed to binding molecules that possess one or more epitope binding sites specific for a CD137 epitope and one or more epitope binding sites specific for a tumor antigen ("TA") epitope (eg, a "Molecule of Union to CD137 x TA"). In one embodiment, such CD137 x TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, which are composed of two, three, four or more of four polypeptide chains and which possess two epitope binding sites each specific to a specific CD137 epitope and two epitope binding sites each specific to an epitope of a TA. Alternatively, such CD137 x TA Binding Molecules will be bispecific molecules, especially trivalent binding bispecific molecules composed of three or more polypeptide chains and having one or two epitope binding sites each specific to a CD137 epitope and one or two epitope binding sites each specific to an epitope of a TA. CD137 x TA Binding Molecules are capable of simultaneously binding to CD137, and a TA. Pharmaceutical compositions containing any binding molecule at CD137 x TA. Methods for the use of such molecules in the treatment of cancer and other diseases and conditions. It also provides binding molecules to CD137, and binding molecules to HER2 / neu, as well as derivatives thereof and uses thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762463353P | 2017-02-24 | 2017-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111000A1 true AR111000A1 (en) | 2019-05-22 |
Family
ID=66669234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100436A AR111000A1 (en) | 2017-02-24 | 2018-02-23 | BISPECIFIC UNION MOLECULES THAT ARE ABLE TO JOIN CD137 AND TUMOR ANTIGENS, AND USES OF THE SAME |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR111000A1 (en) |
-
2018
- 2018-02-23 AR ARP180100436A patent/AR111000A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124791T1 (en) | CD73-SPECIFIC BINDING MOLECULES AND USES THEREOF | |
| CY1123977T1 (en) | ANTI-PD-1 AND ANTI-LAG3 ANTIBODIES FOR THE TREATMENT OF CANCER | |
| EP4389226A3 (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| MX2025000370A (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| CO2018012415A2 (en) | Specific binding proteins and uses thereof | |
| CO2018005932A2 (en) | Bispecific molecules that have immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| BR112016027912A2 (en) | trypecific binding molecule capable of immunospecific binding to three different epitopes, pharmaceutical composition, cancer treatment method, method of treating a disease associated with the presence of a pathogen, anti-ror1 antibody, or ror1 binding fragment, bispecific antibody fragment, bite or single chain antibody, and cancer treatment method | |
| MX2017004669A (en) | Compositions and methods of use for augmented immune response and cancer therapy. | |
| CY1122456T1 (en) | MONOCLONAL ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USES THEREOF FOR THE THERAPEUTIC TREATMENT OF CANCER CACHESIS AND CANCER | |
| MX2016012094A (en) | COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT. | |
| MX2022014914A (en) | COMPOUNDS OF INTERACTION WITH GLYCANS AND METHODS OF USE. | |
| BR112017019785A2 (en) | therapeutic antibodies and their uses | |
| BR112018002844A2 (en) | single domain antibody-based chimeric antigen receptors and methods of use | |
| BR112017003194B8 (en) | ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT SPECIFICALLY BINDS TO HUMAN LAG3, COMPOSITION, AND, USE OF THE ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT OF THESE AND THE COMPOSITION | |
| CL2016002359A1 (en) | Antibodies that bind to human epidermal growth receptor (anti-egfr) and anti-egfr antibody and drug conjugates | |
| EA201891435A1 (en) | HUMANIZED MONOCLONAL ANTIBODIES, MONOCLONAL ANTIBODIES MOUSE OR CHEMERIC MONOCLONAL ANTIBODIES AGAINST CD47 | |
| BR112016016207A2 (en) | ISOLATED ANTI-PD-L1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, ITS PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION, ISOLATED POLYNUCLEOTIDE MOLECULE, VECTOR, CELL, AND USE THEREOF | |
| MX2019007554A (en) | BINDING PROTEINS TO THE ANTI-NEUROPYLIN ANTIGEN, AND THEIR METHODS OF USE. | |
| EA201791050A1 (en) | CONJUGATES OF ANTIBODIES AND MEDICINES | |
| MX369486B (en) | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof. | |
| EA201791270A1 (en) | MODIFIED APRIL-BINDING ANTIBODIES | |
| EA202090387A1 (en) | PROTEINS BINDING NKG2D, CD16 AND FLT3 | |
| CL2021002188A1 (en) | Bispecific antigen-binding molecules and methods of use. | |
| PH12019500802A1 (en) | Antibodies that bind zika virus envelope protein and uses thereof | |
| MX2024003627A (en) | ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOUR NECROSIS FACTOR RECEPTOR (GITR) AND THEIR METHODS OF USE. |